Suzhou Alphamab Co., Ltd.
Works in Cardiovascular · Genetic & rare · Hematology · Metabolic & endocrine
Suzhou Alphamab Co., Ltd. is a clinical trial sponsor. It has 8 active clinical trials with 621 planned participants, in Cardiovascular, Genetic & rare, Hematology and Metabolic & endocrine. Since 2021 it has completed 2 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 8 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Suzhou Alphamab Co., Ltd
Suzhou Alphamab Co., Ltd is lead sponsor of 8 active clinical trials on ClinicalTrials.gov, with 621 planned participants, in Cardiovascular, Genetic & rare, Hematology, Metabolic & endocrine. Since 2021 it has completed 2 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Suzhou Alphamab Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-04-22.
Approve Suite is not affiliated with Suzhou Alphamab Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.